Annji Pharmaceutical Co (ROCO:7754) EBITDA Margin %: -41,845.82% (As of Dec. 2025)


ROCO:7754 Annji Pharmaceutical Co Ltd ROCO:7754
9 GF Score
Price NT$58.70
! 3 Warning Signs
View Full Analysis

What is Annji Pharmaceutical Co EBITDA Margin %?

Annji Pharmaceutical Co ROCO:7754 -0.68% 9 EBITDA Margin % is -41,845.82% as of Dec. 2025. GuruFocus rates ROCO:7754 with a GF Score™ of 9/100. The stock has 3 warning signs investors should review. Among 942 Biotechnology companies, Annji Pharmaceutical Co ranks worse than 89.28% on this metric.

EBITDA Margin % is calculated as EBITDA divided by its Revenue. Annji Pharmaceutical Co's EBITDA for the six months ended in Dec. 2025 was NT$-175.33 Mil. Annji Pharmaceutical Co's Revenue for the six months ended in Dec. 2025 was NT$0.42 Mil. Therefore, Annji Pharmaceutical Co's EBITDA margin for the quarter that ended in Dec. 2025 was -41,845.82%.

Annji Pharmaceutical Co  (ROCO:7754) EBITDA Margin % Explanation

EBITDA Margin % is the ratio of EBITDA divided by net sales or Revenue. It is an performance metric measuring company's operating profitability. EBITDA Margin takes depreciation and amortization, interest expense and tax into account, which makes it easy to compare the relative profitability of companies of different sizes in the same industry.

Annji Pharmaceutical Co EBITDA Margin % Related Terms

Annji Pharmaceutical Co EBITDA Margin % Historical Data

* Premium members only.

The historical data trend for Annji Pharmaceutical Co's EBITDA Margin % can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

Annji Pharmaceutical Co EBITDA Margin % Chart

Annji Pharmaceutical Co Annual Data
Trend Dec21 Dec22 Dec23 Dec24 Dec25
EBITDA Margin %
-10,931.22 -11,968.08 -175.58 -318.57 -4,119.53

Annji Pharmaceutical Co Semi-Annual Data
Dec21 Dec22 Jun23 Dec23 Jun24 Dec24 Jun25 Dec25
EBITDA Margin % Get a 7-Day Free Trial -134.00 -216.69 -804.43 -1,903.45 -41,845.82

ROCO:7754 vs VRTX, REGN, ALNY: EBITDA Margin % Comparison

For the Biotechnology subindustry, Annji Pharmaceutical Co's EBITDA Margin %, along with its competitors' market caps and EBITDA Margin % data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.

Annji Pharmaceutical Co EBITDA Margin % vs Biotechnology Industry

For the Biotechnology industry and Healthcare sector, Annji Pharmaceutical Co's EBITDA Margin % distribution charts can be found below:

* The bar in red indicates where Annji Pharmaceutical Co's EBITDA Margin % falls into.


ROCO:7754
9GF Score
Annji Pharmaceutical Co Ltd ROCO:7754
EBITDA Margin % is just one metric. See GF Score™, valuation, warning signs, and more.
View Full Analysis

Annji Pharmaceutical Co EBITDA Margin % Calculation

EBITDA margin is the ratio of EBITDA divided by net sales or Revenue, usually presented in percent.

Annji Pharmaceutical Co's EBITDA Margin % for the fiscal year that ended in Dec. 2025 is calculated as

EBITDA Margin %=EBITDA (A: Dec. 2025 )/Revenue (A: Dec. 2025 )
=-311.107/7.552
=-4,119.53 %

Annji Pharmaceutical Co's EBITDA Margin % for the quarter that ended in Dec. 2025 is calculated as

EBITDA Margin %=EBITDA (Q: Dec. 2025 )/Revenue (Q: Dec. 2025 )
=-175.334/0.419
=-41,845.82 %

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

Frequently Asked Questions Learn more about EBITDA Margin % →
What does a EBITDA Margin % of -41,845.82% mean?
Annji Pharmaceutical Co (ROCO:7754) has a EBITDA Margin % of -41,845.82% as of Dec. 2025. EBITDA Margin is the ratio of EBITDA divided by net sales or Revenue, usually presented in percent. View historical data on Annji Pharmaceutical Co and its competitors. According to the industry distribution chart, Annji Pharmaceutical Co ranks #841 out of 942 companies in the Biotechnology industry, placing it in the top 89.3%.
Is Annji Pharmaceutical Co's EBITDA Margin % too high?
Annji Pharmaceutical Co's current EBITDA Margin % is -41,845.82%. Based on the distribution chart, Annji Pharmaceutical Co ranks #841 out of 942 companies in the Biotechnology industry, which is in the bottom quartile relative to peers. Overall, Annji Pharmaceutical Co has a GF Score™ of 9/100, reflecting its overall financial health beyond just this single metric.
How does Annji Pharmaceutical Co's EBITDA Margin % compare to VRTX and REGN?
According to the Biotechnology industry distribution chart, Annji Pharmaceutical Co ranks #841 out of 942 companies for EBITDA Margin %. This places Annji Pharmaceutical Co in the lower half of its industry. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good EBITDA Margin % for a Biotechnology company?
A good EBITDA Margin % depends on the Biotechnology industry context. However, EBITDA Margin % should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high EBITDA Margin % mean?
A high EBITDA Margin % can signal that a stock is expensive relative to its fundamentals. EBITDA Margin is the ratio of EBITDA divided by net sales or Revenue, usually presented in percent. View historical data on Annji Pharmaceutical Co and its competitors. Annji Pharmaceutical Co's current EBITDA Margin % is -41,845.82%. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Annji Pharmaceutical Co stock overvalued right now?
Annji Pharmaceutical Co (ROCO:7754) has a current EBITDA Margin % of -41,845.82%. The current EBITDA Margin % is -41,845.82%. Annji Pharmaceutical Co's overall GF Score™ is 9/100 with 3 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is EBITDA Margin % calculated?
EBITDA Margin % is calculated from a company's financial statements. For Annji Pharmaceutical Co (ROCO:7754), the current EBITDA Margin % is -41,845.82% as of Dec. 2025. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.

Annji Pharmaceutical Co Business Description

Address Zhongxiao E. Raod, 16th Floor-6, No. 508, Sector 7, Nangang Distrist, Taipei, TWN, 115011
Annji Pharmaceutical Co Ltd is an R&D based, clinical-stage new drug company dedicated to the development of first-in-class small molecules focusing on indications with highly unmet needs in the therapeutic areas of neurology, dermatology, and inflammatory disorders, including rare diseases such as idiopathic pulmonary fibrosis and Kennedy's disease, or SBMA (Spinal and bulbar muscular atrophy). Its pipeline products include AJ201, AJ302 and AJ303.
9GF Score

Get the complete analysis for ROCO:7754

EBITDA Margin % is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.

NT$58.70
Price